Compare Regeneron Pharmaceuticals Inc (REGN) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Waste Management, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B), while Waste Management, Inc. trades at $209.6 (market cap $83.98B). The key difference: Regeneron Pharmaceuticals Inc and Waste Management, Inc. are close in size by market cap, and Waste Management, Inc. pays the higher dividend (1.8%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Waste Management, Inc. for 130 Days on average.
| REGN | WM | |
|---|---|---|
Market Cap | $76.14B | $83.98B |
Volume | 500,239 | 2,182,180 |
Sector | Health | Industrials |
52-Week High | $852.03 | $246.51 |
52-Week Low | $557.73 | $196.77 |
Typical Hold Time | 107 Days | 130 Days |
Enterprise Value | $70.85B | $106.78B |
Dividend Yield | 0.51% | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Waste Management (WM) trades at $208.94, up 0.51% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with $25.2B revenue in 2025, 11.12% net margin, and consistent earnings beats in recent quarters. Recent news highlights WM's defensive business model and dividend reliability, while analyst consensus remains strongly positive with 57% buy ratings.
WM presents a compelling long-term investment with stable cash flows and dividend growth potential, though elevated debt levels and near-term technical weakness warrant caution. The stock's premium valuation (P/E 29.55) reflects quality but limits near-term upside absent significant earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
